Kooij Louise Frederika Buys Shares of NAMS $NAMS
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kooij Louise Frederika, Chief Accounting Officer at NewAmsterdam Pharma Company N.V. ($NAMS), bought 40,000 shares at an average price of $11.28, for a total transaction of $451,000. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
NewAmsterdam Pharma Company N.V. Stock Up 26.0%
Shares of NewAmsterdam Pharma Company N.V. ($NAMS) traded around $32.63 on Thursday, up 26.0% for the day.
NewAmsterdam Pharma Company N.V. Earnings
Analysts Set New Price Targets
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Get NewAmsterdam Pharma Company N.V. alerts
New 13F filings, insider trades, and analyst moves on $NAMS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.